Metastatic brain tumor secondary to pancreatic adenocarcinoma
Article Sidebar
Main Article Content
Abstract
Pancreatic neoplasm is represented by the subtype Adenocarcinoma in 90% to 95% of cases, characterized by the high lethality rate of its presentations; however, cases of progression in the brain site are manifested in only 0.1% to 0.3% of all the cases. The present study aims to report a rare case of a patient undergoing treatment for pancreatic cancer, which had a median overall survival significantly higher than the median time related to such neoplasm, and during the final evolution of the disease progression, an unusual associated with symptomatic brain metastatic activity, was evidenced, thus we correlated the current medical literary data to the events presented by the reported patient. Thus, the reported case becomes of extreme clinical relevance for the study of modern clinical oncology.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van Laethem JL, Conroy T, Arnold D; ESMO Guidelines Committee. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann of Oncol. 2015;26(56-68). doi:10.1093/annonc/mdv295.
National Cancer Institute. Ministry of Health. Health Care Secretariat. Estimates 2008: cancer incidence in Brazil. Rio de Janeiro: INCA; 2007.
Silva CSHA da, Lucas SFLM, Nakatsu E, Moricz A, Silva RA, Pacheco Jr AM, Campo T. Pancreatic adenocarcinoma in a young patient: case report. Arch Med Hosp Fac Cienc Med Santa Casa São Paulo. 2011; 56(1):36-9.
[ Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2014. Ann Oncol. 2014; 25(8): 1650-6. https://doi.org/10.1093/annonc/mdu138.
Yeo TP. Demographics, epidemiology, and inheritance of pancreatic ductal adenocarcinoma. Semin Oncol. 2015; 42(1):8-18. https://doi.org/10.1053/j.seminoncol.2014.12.002.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. doi: 10.3322/caac.21551.
Maisonneuve P, Lowenfels AB. Risk factors for pancreatic cancer: a summary review of meta-analytical studies. Int J Epidemiol. 2015;44(1): 186-98. https://doi.org/10.1093/ije/dyu240.
Dalal K, Khrizman P, Chaaya, AA. Isolated Brain Metastasis From Pancreatic Cancer in Lynch Syndrome. Am J Gastroenterol. 2019;114(1):S697. doi: 10.14309/01.ajg.0000594536.59856.1f
Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019; 381(4):317-27. doi:10.1056/nejmoa1903387
Orsini M, Sarmet A, Consídera D, Barbosa MD, Nascimento LM, Leite MAA, Souza JA. Brain metastases in pancreatic carcinoma: a rare situation. Rev Bras Neurol. 2014;50(4):88.
Matsumoto H, Yoshida Y. Brain metastasis from pancreatic cancer: a case report and literature review. Asian J Neurosurg. 2015;10(1):35-9. doi: 10.4103/1793-5482.151507
Lemke J, Scheele J, Kapapa T, Wirtz CR, Henne-Bruns D, Kornmann M. Brain metastasis in pancreatic cancer. Int J Mol Sci. 2013 Feb 19;14(2):4163-73. doi: 10.3390/ijms14024163.
Rao R, Sadashiv SK, Goday S, Monga D. An extremely rare case of pancreatic cancer presenting with leptomeningeal carcinomatosis and synchronous intraparenchymal brain metastasis. Gastrointest Cancer Res. 2013 May;6(3):90-2.
Kuratsu J, Murakami M, Uemura S, Ushio Y. Brain and skull metastases of hepatic or pancreatic cancer--report of six cases. Neurol Med Chir (Tokyo). 1990 Jul;30(7):476-82. doi: 10.2176/nmc.30.476.